There are so many things wrong with this post.
“But
There are so many things wrong with this post.
“But what I know , reports from many physicians from around the world , including USA , and some studies showing , that if one use at the beginning of infection , many patients are not hospitalized.”
Please, share the link to the FDA trial data that proves your statements above.
“are you saying this is not accurate ..For me what happen to my patients is the only important thing !!!
He is a critical care physician, who’s caring for COVID19 patients, and he’s telling you that hydroxychloroquine isn’t working in the patients he’s treated it with. But you still don’t believe him?
“And IMO your patients in ICU should not be on Doxycycline and very high dose of prednisone, dose which may kill many in any age, but specially after 60.”
When I did my rotations through the ICU, which was a number of years ago, there were no dermatologists instructinf the ICU doctors how to care for patients. Why? Because their dermatologists. I don’t think he’d walk over to the derm clinic and tell you how to treat melanoma.
“they all should be on Leronlimab... You all should know and use it by now , big University Hospital in Long Island”
At least you ended your post on a positive note, although we need the trials to prove leronlimab’s efficacy as well. This is a waiting game that is going to be painful for investors and for people sick with COVID19.
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...
Continue Reading
Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...
Continue Reading
Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...
Continue Reading
GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...
Continue Reading
Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...
Continue Reading
Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...
Continue Reading
AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...
Continue Reading
Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...
Continue Reading
Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...
Continue Reading
Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....
Continue Reading
Top 5 Most Recently Viewed Articles
Shell plc made some serious moves back in September 2024 that had traders scratching their heads and looking for the fine print. They let loose a slew of notifications about share transactions by its Persons Discharging Managerial Responsibilities (PDMRs), making waves in the market. This isn’t just corporate fluff; it’s a playbook for transparency and compliance that...
Continue Reading
Unpacking the Explosive Allegations Against zSpace You think you're safe diving into augmented reality stocks, and then a bombshell lands. zSpace, Inc. (NASDAQ:ZSPC), a supposed leader in AR and VR educational tech, finds itself in the swirling midst of a class action lawsuit. Investors are rattled, and they're not just buzzing because their portfolios took a hit. There's...
Continue Reading
WisdomTree Introduces Earn-Until-You-Spend Feature WisdomTree, Inc. (NYSE: WT), a leader in financial innovation, has recently announced a significant enhancement to its user experience with the introduction of a new feature allowing customers to utilize their accrued interest from the WisdomTree Government Money Market Digital Fund (WTGXX) as a funding source for the...
Continue Reading
AVITA Medical to Report Financial Results AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a prominent company in therapeutic acute wound care, has made headlines with its upcoming financial disclosure. The firm is set to unveil its third-quarter financial results for 2025 after the U.S. markets close on the scheduled date. This announcement is anticipated by investors who...
Continue Reading
Hyperscale Data's Commendable Dividend Achievement LAS VEGAS — Hyperscale Data, Inc. (NYSE: GPUS) proudly announced it has consistently paid cash dividends for twenty-eight consecutive months on its Series D Preferred Stock. This dividend, amounting to 13.00% annually, equates to approximately $0.2708 for each share, paid monthly. This remarkable track record...
Continue Reading